Skip to main content
Article thumbnail
Location of Repository

All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD

By S. McCutcheon, A.R. Alejo Blanco, E.F. Houston, C. de Wolf, B.C. Tan, A. Smith, M.H. Groschup, N. Hunter, V.S. Hornsey, I.R. MacGregor, C. V. Prowse, M. Turner and J.C. Manson

Abstract

Variant CJD (vCJD) is an incurable, infectious human disease, likely arising from the consumption of BSE-contaminated meat products. Whilst the epidemic appears to be waning, there is much concern that vCJD infection may be perpetuated in humans by the transfusion of contaminated blood products. Since 2004, several cases of transfusion-associated vCJD transmission have been reported and linked to blood collected from pre-clinically affected donors. Using an animal model in which the disease manifested resembles that of humans affected with vCJD, we examined which blood components used in human medicine are likely to pose the greatest risk of transmitting vCJD via transfusion. We collected two full units of blood from BSE-infected donor animals during the pre-clinical phase of infection. Using methods employed by transfusion services we prepared red cell concentrates, plasma and platelets units (including leucoreduced equivalents). Following transfusion, we showed that all components contain sufficient levels of infectivity to cause disease following only a single transfusion and also that leucoreduction did not prevent disease transmission. These data suggest that all blood components are vectors for prion disease transmission, and highlight the importance of multiple control measures to minimise the risk of human to human transmission of vCJD by blood transfusion

Publisher: Public Library of Science
Year: 2011
OAI identifier: oai:eprints.gla.ac.uk:57809
Provided by: Enlighten

Suggested articles

Citations

  1. (1996). A new variant of Creutzfeldt-Jakob disease in the UK. doi
  2. (2010). B cells and platelets harbor prion infectivity in the blood of CWD-infected deer. doi
  3. (2002). Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. doi
  4. (1998). Cerebral targeting indicates vagal spread of infection in hamsters fed with scrapie.
  5. (2006). Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. doi
  6. (2001). Clinical signs, histopathology and genetics of experimental transmission of BSE and natural scrapie to sheep and goats. doi
  7. (1999). Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. doi
  8. (2011). Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. doi
  9. (2001). Detection of variant Creutzfeld-Jakob disease infectivity in extraneural tissues. doi
  10. (2001). Distribution of the prion protein in sheep terminally affected with BSE following experimental oral transmission. doi
  11. (2004). Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. doi
  12. (1999). Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. doi
  13. (2005). Guidelines for the Blood Transfusion Services in the United Kingdom.
  14. (2005). Immunohistochemical characteristics of disease-associated PrP are not altered by host genotype or route of inoculation following infection of sheep with bovine spongiform encephalopathy. doi
  15. (2003). Inactivation of viral and prion pathogens by gamma-irradiation under conditions that maintain the integrity of human albumin. doi
  16. (2009). Infectious prions in pre-clinical deer and transmission of chronic wasting disease solely by environmental exposure. doi
  17. (2006). Infectious prions in the saliva and blood of deer with chronic wasting disease. doi
  18. (1996). Molecular analysis of prion strain variation and the aetiology of ‘new variant’ doi
  19. (2009). Neuroinvasion in sheep transmissible spongiform encephalopathies: the role of the haematogenous route. doi
  20. (2006). Ovine prion protein variant A(136) R(154)L(168)Q(171) increases resistance to experimental challenge with bovine spongiform encephalopathy agent. doi
  21. (2009). Paracrine diffusion of PrP(C) and propagation of prion infectivity by plasma membrane-derived microvesicles. doi
  22. (2004). Passage of murine scrapie prion protein across the mouse vascular blood-brain barrier. doi
  23. (2008). Pathogenesis of bovine spongiform encephalopathy in sheep. doi
  24. (1979). Pathogenesis of mouse scrapie: dynamics of agent replication in spleen, spinal cord and brain after infection by different routes. doi
  25. (2004). Peripheral tissue involvement in sporadic, latrogenic, and variant CreutzfeldtJakob disease - An immunohistochemical, quantitative, and biochemical study.
  26. (2010). Position statement: Creutzfeld-Jacob Disease.
  27. (2004). Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. doi
  28. (2004). Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. doi
  29. (1999). Preliminary assessment of whole-blood, red-cell and platelet- leucodepleting filters for possible induction of prion release by leucocyte fragmentation during room temperature processing. doi
  30. (2009). Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. doi
  31. (2004). Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. doi
  32. (2008). Prion diseases are efficiently transmitted by blood transfusion in sheep. doi
  33. (2009). PRNP variation in UK sporadic and variant Creutzfeldt Jakob disease highlights genetic risk factors and a novel non-synonymous polymorphism. doi
  34. (2005). Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. doi
  35. (2009). Protective effect of the T112 PrP variant in sheep challenged with bovine spongiform encephalopathy. doi
  36. (2006). Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. doi
  37. (2006). Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands. doi
  38. (2004). Review: pathology of variant Creutzfeldt-Jakob disease. doi
  39. (2002). Scrapie infectivity in hamster blood is not associated with platelets. doi
  40. (2003). Similar levels of infectivity in the blood of mice infected with humanderived vCJD and GSS strains of transmissible spongiform encephalopathy. doi
  41. (1978). Studies of the lymphoreticular system in the pathogenesis of scrapie: the role of spleen and thymus. doi
  42. (1998). The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. doi
  43. (2006). The effects of leukodepletion on the generation and removal of microvesicles and prion protein in blood components. doi
  44. (2006). The neuropathologic phenotype of experimental ovine BSE is maintained after blood transfusion. doi
  45. (2004). Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. doi
  46. (2011). Transfusion Services. Transfusion Medicine Epidemiology Review
  47. (2000). Transmission of BSE by blood transfusion in sheep. doi
  48. (2002). Transmission of prion diseases by blood transfusion. doi
  49. (1997). Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent.
  50. (2008). TSE pathogenesis in cattle and sheep. doi
  51. (2005). Use of a new immunoassay to measure PrPSc levels in scrapie-infected sheep brains reveals PrP genotypespecific differences. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.